MIRACLE Medical Technology Act of 2025

HR 661, the MIRACLE Medical Technology Act of 2025, establishes a formal US-Israel program to coordinate collaboration on developing and delivering healthcare products and services. It directs the Secretary of Health and Human Services to create joint initiatives - including shared research on medical devices and pharmaceuticals, regulatory alignment (like FDA-Israel regulatory data sharing), innovation hubs for startups, and telemedicine infrastructure - leveraging $8 million annually from 2026-2030. The bill directly affects US health agencies (HHS, FDA), Israeli health authorities, and medical technology companies in both countries. Key mechanisms include creating a US-Israel Health Care Collaboration Center, promoting joint manufacturing facilities for biological products, and standardizing data sharing for research. This focuses on concrete policy changes to enhance bilateral medical innovation and healthcare delivery.